UK competition authority flags Demant divestment of Oticon as problematic
The UK Competition and Markets Authority thinks that the sale of Demant’s business unit to Cochlear could result in ”a substantial lessening of competition.” (Updated)
by christian bundgaard, translated by daniel pedersen
On Thursday, Demant reported that the UK Competition and Markets Authority (CMA) has scrutinized a proposed transaction involving Demant and Cochlear, saying it might result in ”a substantial lessening of competition” should it be allowed to go through.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Demant expecting to close divestment of Oticon Medical in Q2
For subscribers
